Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedAug 28, 2025
DataAggregated Company Financials
Companies9
  • 7D0.4%
  • 3M7.4%
  • 1Y0.8%
  • YTD10.5%

In the last week, Pharma has been flat. Furthermore, the industry has been flat for the past year as well. Earnings are forecast to grow by 13% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 28 Aug 2025CHF 483.1bCHF 120.6bCHF 21.0b30.9x23x4x
Sat, 26 Jul 2025CHF 460.3bCHF 118.6bCHF 19.5b26.6x23.7x3.9x
Mon, 23 Jun 2025CHF 444.4bCHF 118.7bCHF 19.2b24.9x23.2x3.7x
Wed, 21 May 2025CHF 439.5bCHF 119.4bCHF 19.3b25.3x22.7x3.7x
Fri, 18 Apr 2025CHF 413.0bCHF 117.5bCHF 18.4b24.6x22.4x3.5x
Sun, 16 Mar 2025CHF 476.6bCHF 121.8bCHF 19.2b29.4x24.9x3.9x
Tue, 11 Feb 2025CHF 476.1bCHF 123.2bCHF 19.3b22.8x24.7x3.9x
Thu, 09 Jan 2025CHF 442.7bCHF 119.7bCHF 21.4b18.5x20.7x3.7x
Sat, 07 Dec 2024CHF 428.1bCHF 117.6bCHF 21.1b18.3x20.3x3.6x
Mon, 04 Nov 2024CHF 452.2bCHF 117.1bCHF 21.0b19.6x21.5x3.9x
Wed, 02 Oct 2024CHF 448.6bCHF 114.6bCHF 19.3b21.4x23.3x3.9x
Fri, 30 Aug 2024CHF 476.3bCHF 114.7bCHF 19.3b22.8x24.7x4.2x
Sun, 28 Jul 2024CHF 463.8bCHF 116.7bCHF 19.7b22.1x23.6x4x
Tue, 25 Jun 2024CHF 438.6bCHF 116.1bCHF 19.7b34.4x22.2x3.8x
Thu, 23 May 2024CHF 413.5bCHF 113.7bCHF 20.0b41.4x20.7x3.6x
Sat, 20 Apr 2024CHF 393.9bCHF 112.6bCHF 19.5b35.4x20.2x3.5x
Mon, 18 Mar 2024CHF 389.3bCHF 110.9bCHF 19.2b37.3x20.2x3.5x
Wed, 14 Feb 2024CHF 379.8bCHF 110.8bCHF 19.7b23.7x19.2x3.4x
Fri, 12 Jan 2024CHF 413.9bCHF 119.4bCHF 18.7b27x22.2x3.5x
Sun, 10 Dec 2023CHF 401.6bCHF 121.2bCHF 18.9b24.3x21.3x3.3x
Tue, 07 Nov 2023CHF 386.0bCHF 122.3bCHF 19.0b23.7x20.3x3.2x
Thu, 05 Oct 2023CHF 404.5bCHF 113.7bCHF 18.2b42.7x22.2x3.6x
Sat, 02 Sep 2023CHF 405.5bCHF 112.1bCHF 18.0b48.2x22.6x3.6x
Mon, 31 Jul 2023CHF 415.6bCHF 114.5bCHF 19.2b48x21.6x3.6x
Wed, 28 Jun 2023CHF 418.2bCHF 115.0bCHF 18.9b36.7x22.2x3.6x
Fri, 26 May 2023CHF 435.1bCHF 115.6bCHF 18.9b39x23x3.8x
Sun, 23 Apr 2023CHF 441.0bCHF 114.6bCHF 18.8b42.9x23.5x3.8x
Tue, 21 Mar 2023CHF 397.6bCHF 116.3bCHF 19.0b26.4x20.9x3.4x
Thu, 16 Feb 2023CHF 407.4bCHF 116.1bCHF 19.0b29.2x21.4x3.5x
Sat, 14 Jan 2023CHF 433.3bCHF 117.3bCHF 34.7b22.4x12.5x3.7x
Mon, 12 Dec 2022CHF 447.0bCHF 117.5bCHF 34.8b23.4x12.8x3.8x
Wed, 09 Nov 2022CHF 453.6bCHF 120.5bCHF 36.1b22.5x12.6x3.8x
Fri, 07 Oct 2022CHF 445.3bCHF 120.9bCHF 37.2b20.7x12x3.7x
Sun, 04 Sep 2022CHF 447.5bCHF 120.5bCHF 37.0b21.2x12.1x3.7x
Price to Earnings Ratio

12.1x


Total Market Cap: CHF 447.5bTotal Earnings: CHF 37.0bTotal Revenue: CHF 120.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 20.6x202320242025
Current Industry PE
  • Investors are optimistic on the Swiss Pharmaceuticals industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 22.7x which is higher than its 3-year average PE of 20.6x.
  • The industry is trading close to its 3-year average PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 17% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market-0.56%
Healthcare0.057%
Pharma0.41%
Pharma0.41%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GALD Galderma GroupCHF 140.205.3%
+CHF 1.7b		73.9%PE109.7x
SDZ Sandoz GroupCHF 50.523.7%
+CHF 771.0m		34.5%PE119.5x
ROG Roche HoldingCHF 262.600.08%
+CHF 170.1m		-6.9%PE23.7x
COPN Cosmo PharmaceuticalsCHF 61.5010.0%
+CHF 89.3m		-22.3%PE17.5x
NWRN Newron PharmaceuticalsCHF 8.8815.3%
+CHF 23.6m		12.0%PE12x

Latest News

GALD
CHF 140.20
Galderma Group
7D
5.3%
1Y
73.9%

Global Aesthetics And Aging Trends Will Drive Expansion

Analysts have raised Galderma Group's price target to CHF140.69, reflecting strengthened conviction in early Nemluvio traction, robust pipeline execution, and sustained market share gains across dermatology. Analyst Commentary Bullish analysts cite strong early commercial traction and blockbuster potential for Nemluvio following its recent launch.
NWRN
CHF 8.88
Newron Pharmaceuticals
7D
15.3%
1Y
12.0%
ROG
CHF 262.60
Roche Holding
7D
0.08%
1Y
-6.9%

Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

Aug 20
Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)
SDZ
CHF 50.52
Sandoz Group
7D
3.7%
1Y
34.5%

Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities

Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.
DESN
CHF 291.00
Dottikon ES Holding
7D
-0.5%
1Y
12.8%

Does Dottikon ES Holding (VTX:DESN) Have A Healthy Balance Sheet?

Aug 13
Does Dottikon ES Holding (VTX:DESN) Have A Healthy Balance Sheet?
NOVN
CHF 101.98
Novartis
7D
-0.4%
1Y
0.5%
ADXN
CHF 0.058
Addex Therapeutics
7D
-0.7%
1Y
-17.1%
COPN
CHF 61.50
Cosmo Pharmaceuticals
7D
10.0%
1Y
-22.3%
BIOV
CHF 27.10
BioVersys
7D
5.0%
1Y
n/a
CURN
CHF 11.45
Curatis Holding
7D
-3.8%
1Y
118.5%